STAAR Surgical (NASDAQ:STAA) Shares Bought by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lifted its position in shares of STAAR Surgical (NASDAQ:STAA) by 64.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 56,260 shares of the medical instruments supplier’s stock after buying an additional 22,021 shares during the quarter. Mutual of America Capital Management LLC’s holdings in STAAR Surgical were worth $1,756,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Anatole Investment Management Ltd acquired a new position in STAAR Surgical during the first quarter worth about $130,633,000. Morgan Stanley lifted its stake in STAAR Surgical by 154.2% in the 3rd quarter. Morgan Stanley now owns 830,026 shares of the medical instruments supplier’s stock valued at $33,350,000 after buying an additional 503,488 shares in the last quarter. Vanguard Group Inc. grew its holdings in STAAR Surgical by 10.0% during the 3rd quarter. Vanguard Group Inc. now owns 5,425,627 shares of the medical instruments supplier’s stock valued at $218,002,000 after buying an additional 492,500 shares during the last quarter. BlackRock Inc. grew its holdings in STAAR Surgical by 8.3% during the 2nd quarter. BlackRock Inc. now owns 6,339,320 shares of the medical instruments supplier’s stock valued at $333,258,000 after buying an additional 486,781 shares during the last quarter. Finally, Clearbridge Investments LLC purchased a new position in STAAR Surgical during the first quarter worth $32,339,000. 96.70% of the stock is currently owned by hedge funds and other institutional investors.

STAAR Surgical Stock Performance

Shares of STAA stock opened at $46.39 on Monday. STAAR Surgical has a one year low of $26.66 and a one year high of $73.13. The company has a 50 day moving average price of $38.19 and a 200 day moving average price of $35.39. The firm has a market capitalization of $2.27 billion, a price-to-earnings ratio of 107.88 and a beta of 0.86.

STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings data on Monday, February 26th. The medical instruments supplier reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.01). STAAR Surgical had a net margin of 6.62% and a return on equity of 8.73%. The firm had revenue of $76.27 million during the quarter, compared to analyst estimates of $75.94 million. During the same period in the prior year, the firm earned $0.04 earnings per share. The business’s revenue for the quarter was up 19.1% on a year-over-year basis. As a group, equities analysts forecast that STAAR Surgical will post 0.03 EPS for the current fiscal year.

Insider Transactions at STAAR Surgical

In other news, Director Aimee S. Weisner bought 1,750 shares of STAAR Surgical stock in a transaction dated Thursday, March 14th. The shares were acquired at an average cost of $38.11 per share, with a total value of $66,692.50. Following the completion of the transaction, the director now owns 10,864 shares in the company, valued at approximately $414,027.04. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 1.10% of the company’s stock.

Analyst Upgrades and Downgrades

STAA has been the topic of several recent research reports. Mizuho upped their price objective on STAAR Surgical from $45.00 to $53.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a report on Thursday, April 4th. William Blair upgraded shares of STAAR Surgical from a “market perform” rating to an “outperform” rating in a report on Thursday, April 4th. Canaccord Genuity Group boosted their price objective on shares of STAAR Surgical from $32.00 to $46.00 and gave the company a “hold” rating in a research report on Monday, April 8th. Finally, Stifel Nicolaus restated a “buy” rating and set a $50.00 target price on shares of STAAR Surgical in a research report on Monday, April 1st. Seven investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, STAAR Surgical presently has an average rating of “Hold” and an average target price of $46.38.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.